GlassScriptPhysician profile
Amy R Wooldridge
NPI 1386624070
$1,980.80
in general payments reported to CMS, 2019-2025
43 companies · $20.05 in 2025
The $20.05 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $312 · 2021: $283 · 2022: $388 · 2023: $421 · 2024: $110 · 2025: $20.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $192.66 | 2019-2024 | Ozempic, Rybelsus |
| Arbor Pharmaceuticals, INC. | $168.48 | 2020 | |
| Amgen INC. | $148.99 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $128.89 | 2019-2023 | Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $111.91 | 2019-2024 | Tezspire, Farxiga |
| Abbott Laboratories | $91.71 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.38 | 2019-2023 | Stiolto Respimat |
| Astellas Pharma US INC | $78.83 | 2019-2020 | |
| Organogenesis INC. | $75.18 | 2022-2023 | Puraply |
| Pfizer INC. | $68.91 | 2019-2023 | |
| Allergan, INC. | $65.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $60.66 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Grifols USA, LLC | $46.98 | 2020-2022 | |
| Mylan Specialty L.P. | $41.16 | 2019-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $41.11 | 2022-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wooldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.